Regeneron Pharmaceuticals said on Friday it would stop enrolling patients receiving advanced COVID-19 care in a trial testing its experimental antibody treatment in hospitalized patients, based on the recommendation of an independent safety board.
Britain's GSK cautioned full-year earnings would likely come in at the lower end of its forecast range after the COVID-19 pandemic took a toll on its vaccines unit, with people in the United States shunning visits to their physician for their shots.
Eli Lilly and Co on Tuesday aimed to ease investor concerns about its COVID-19 antibody treatment after a trial of the therapy failed to show a benefit in hospitalized patients.
Pfizer Inc and Johnson & Johnson are seeking input from a U.S. Food and Drug Administration advisory committee on retaining and attracting volunteers for COVID-19 vaccine trials after a vaccine becomes available, if they know they might receive a placebo.
Canadian drugmaker Bausch Health Companies Inc said on Thursday it would spin off its eye care unit, Bausch + Lomb, into a separate publicly listed company, seven years after acquiring it for nearly $9 billion.
Aug 6 Canadian drugmaker Bausch Health Companies
Inc said on Thursday it would spin off its eye care
unit, Bausch + Lomb, into a separate publicly listed company,
seven years after acquiring it for nearly $9 billion.
Moderna Inc said on Wednesday smaller volume agreements for its experimental coronavirus vaccine have been priced in the range of $32 to $37 per dose, higher than the price set by the U.S. deal for Pfizer Inc's vaccine candidate.
Young people who are hitting nightclubs and beaches are leading a rise in fresh coronavirus cases across the world, with the proportion of those aged 15 to 24 who are infected rising three-fold in about five months, the World Health Organization said.